AstraZeneca PLC, AZN is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in United Kingdom, AstraZeneca PLC, AZN has a market cap of 83247.83. Since its IPO date on the 5/17/1993, AstraZeneca PLC, AZN performance year to date is 1.10%. Today AstraZeneca PLC, AZN has gained -1.20%, with a current price of 32.81.
Ownership of the company is 0.50% for insider ownership while institutional ownership is 12.20%. The management of the company have seen the company have a payout ratio of 108.10%. Return of assets are at 3.70%, with return on investment at 11.50%.
In terms of debt levels and profit levels, AstraZeneca PLC, AZN is seeing a long-term debt/equity of 1.22. While Total debt/equity is 1.3. With a profit margin of 9.20%, this is combined with a gross margin of 82.20%, and operating margin of 15.00%. AstraZeneca PLC ability to meet debt levels, with a current ratio of 0.9, while the quick ratio is 0.8.
For the last year AstraZeneca PLC, AZN has seen a EPS growth of 128.90%. A performance for the year of 11.84%. The 52-week high is -5.11%, and the 52-week low is 23.28%. The average volume for AstraZeneca PLC, AZN is 4751200.
With a target price of 35.5, can AstraZeneca PLC, AZN reach this target? Looking at the value indicators of AstraZeneca PLC, AZN. AstraZeneca PLC has a P/E of 37.37 and a forward P/E of 14.52. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. AstraZeneca PLC also has a P/S and a P/B of 3.46 and 6.13 respectively. For P/cash, AstraZeneca PLC has a value of 17.92, while it is *TBA for P/free cash flow.
At the current price of 32.81, AstraZeneca PLC has a dividend yield of 2.74%. We see a return on equity of 13.90%.
Looking more long-term AstraZeneca PLC, is projected to get an EPS growth for the next five years of -1.00%. In the short-term an EPS growth of -8.50% in the next year is forecasted. This is after a EPS growth of 128.90% for this year and for the last five years a -16.70% growth has been seen.